U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07553338) titled 'Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease' on April 21.
Brief Summary: The present study will administer the drug leronlimab to 20 participants who are above 50 years old with Alzheimer's disease (AD) or mild cognitive impairment due to AD. While leronlimab is considered safe in other diseases like Human Immunodeficiency Virus (HIV) and certain types of breast cancer, its safety and tolerability in AD will be tested for the first time. The main purpose of this study is to learn:
1. Is this drug safe for participants with AD and MCI due to AD?
2. Does leronlimab change levels of br...